SCHEMBL3409636

SCHEMBL3409636

O=[PH](O)N1CCNCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19716242 0.97 CA2 (0.36)
SCHEMBL28849785 0.78
SCHEMBL15129698 0.77 CA2 (0.35)
SCHEMBL28438646 0.74
Phosphonic Acid SCHEMBL5482535 0.71
SCHEMBL23531715 0.71 ALDH1A1 (0.35)
SCHEMBL29133667 0.71 ALDH1A1 (0.35)
SCHEMBL15904389 0.71 ALDH1A1 (0.35)
Methylpiperazine SCHEMBL28969663 0.70 PHGDH (0.38)
Piperazine SCHEMBL1483972 0.68 HIF1A (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976279-B2 Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors EMORY UNIVERSITY (US) 2024-05-07 US claimed
US-20220090079-A1 Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors UNIV EMORY (US) 2022-03-24 US claimed
US-11149274-B2 Methods and compositions for managing vascular conditions EMORY UNIVERSITY (US) 2021-10-19 US claimed
US-20200095583-A1 Methods and Compositions for Managing Vascular Conditions UNIV EMORY (US) 2020-03-26 US claimed
US-20190112603-A1 Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors UNIV EMORY (US) 2019-04-18 US claimed
US-20180362984-A1 Methods and Compositions for Managing Vascular Conditions UNIV EMORY (US) 2018-12-20 US claimed
US-9932585-B2 Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto EMORY UNIVERSITY (US) 2018-04-03 US claimed
US-20170051284-A1 Manipulating MicroRNA for the Management of Neurological Diseases or Conditions and Compositions Related Thereto NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-02-23 US claimed
US-9458458-B2 Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto EMORY UNIVERSITY (US) 2016-10-04 US claimed
US-20160002628-A1 METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS EMORY UNIVERSITY 2016-01-07 US claimed
US-20150133522-A1 MANIPULATING MICRORNA FOR THE MANAGEMENT OF NEUROLOGICAL DISEASES OR CONDITIONS AND COMPOSITIONS RELATED THERETO NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-14 US claimed
US-20140309280-A1 ASSAYS FOR MICRO-RNA-182 AS A BIOMARKER FOR MUSCLE ATROPHY AND THERAPEUTIC APPLICATIONS EMORY UNIVERSITY (US) 2014-10-16 US claimed
WO-2014164753-A1 METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS EMORY UNIVERSITY (US) 2014-10-09 WO claimed
EP-4392558-A1 ANTISENSE OLIGONUCLEOTIDES HAVING ONE OR MORE ABASIC UNITS Sarepta Therapeutics, Inc. (US) 2024-07-03 EP disclosed
EP-4387676-A2 DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES Sarepta Therapeutics, Inc. (US) 2024-06-26 EP disclosed
US-11976279-B2 Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors EMORY UNIVERSITY (US) 2024-05-07 US disclosed
EP-2132284-A2 ADDITIVE FORMULATION SUITED FOR ANTI-STATIC FINISHING AND IMPROVEMENT OF THE ELECTRICAL CONDUCTIVITY OF INANIMATE ORGANIC MATERIAL BASF SE (DE) 2009-12-16 EP disclosed
CN-100475824-C Novel phosphonic acid compounds as inhibitors of serine proteases ORTHO MCNEIL PHARM INC (US) 2009-04-08 CN disclosed
WO-2008107371-A2 ADDITIVE FORMULATION SUITED FOR ANTI-STATIC FINISHING AND IMPROVEMENT OF THE ELECTRICAL CONDUCTIVITY OF INANIMATE ORGANIC MATERIAL BASF SE (DE) 2008-09-12 WO disclosed
CN-1832950-A Novel phosphonic acid compounds as inhibitors of serine proteases ORTHO MCNEIL PHARM INC (US) 2006-09-13 CN disclosed